{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:33:43Z","timestamp":1785458023162,"version":"3.56.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.numecd.2020.05.032","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T11:46:22Z","timestamp":1592394382000},"page":"1601-1608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effect of insulin secretagogues on major cardiovascular events and all-cause mortality: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9759-9408","authenticated-orcid":false,"given":"Edoardo","family":"Mannucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9349-828X","authenticated-orcid":false,"given":"Matteo","family":"Monami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Candido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basilio","family":"Pintaudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.numecd.2020.05.032_bib1","article-title":"[The new National Guidelines System in Italy: a first evaluation]","volume":"36","author":"Iannone","year":"2019","journal-title":"G Ital Nefrol : organo ufficiale della Societa italiana di nefrologia"},{"issue":"2","key":"10.1016\/j.numecd.2020.05.032_bib2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"10.1016\/j.numecd.2020.05.032_bib3","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jclinepi.2010.07.001","article-title":"Agree II: advancing guideline development, reporting and evaluation in health care","volume":"63","author":"Brouwers","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.numecd.2020.05.032_bib4","first-page":"264","article-title":"Preferred reporting items for systematic reviews and meta-analyses","volume":"151","author":"Moher","year":"2009","journal-title":"the PRISMA statement"},{"issue":"2","key":"10.1016\/j.numecd.2020.05.032_bib5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.13888","article-title":"Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: an updated meta-analysis and subgroup analysis of randomized controlled trials","volume":"22","author":"Mannucci","year":"2020","journal-title":"Diabetes Obes Metabol"},{"issue":"10166","key":"10.1016\/j.numecd.2020.05.032_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.numecd.2020.05.032_bib7","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2337\/dc14-0024","article-title":"HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin","volume":"37","author":"Ahren","year":"2014","journal-title":"Diabetes Care"},{"issue":"9131","key":"10.1016\/j.numecd.2020.05.032_bib8","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"9131","key":"10.1016\/j.numecd.2020.05.032_bib9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.numecd.2020.05.032_bib10","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","article-title":"Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial","volume":"5","author":"Vaccaro","year":"2017","journal-title":"The lancet Diabetes & endocrinology"},{"issue":"12","key":"10.1016\/j.numecd.2020.05.032_bib11","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1055\/s-0029-1234042","article-title":"Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes","volume":"41","author":"Foley","year":"2009","journal-title":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme"},{"issue":"21","key":"10.1016\/j.numecd.2020.05.032_bib12","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","article-title":"Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial","volume":"296","author":"Mazzone","year":"2006","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.numecd.2020.05.032_bib13","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.2337\/dc12-0719","article-title":"Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease","volume":"36","author":"Hong","year":"2013","journal-title":"Diabetes Care"},{"issue":"23","key":"10.1016\/j.numecd.2020.05.032_bib14","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.numecd.2020.05.032_bib15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1464-5491.2006.01801.x","article-title":"Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes","volume":"23","author":"Perriello","year":"2006","journal-title":"Diabet Med : a journal of the British Diabetic Association"},{"issue":"5","key":"10.1016\/j.numecd.2020.05.032_bib16","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0149-2918(04)90068-9","article-title":"Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trial","volume":"26","author":"Tan","year":"2004","journal-title":"Clin Therapeut"},{"issue":"3","key":"10.1016\/j.numecd.2020.05.032_bib17","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2337\/diabetes.51.3.808","article-title":"Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes","volume":"51","author":"Scognamiglio","year":"2002","journal-title":"Diabetes"},{"issue":"2 Suppl","key":"10.1016\/j.numecd.2020.05.032_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1056-8727(02)00272-6","article-title":"Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions","volume":"17","author":"Gribble","year":"2003","journal-title":"J Diabetes Complicat"},{"issue":"6","key":"10.1016\/j.numecd.2020.05.032_bib19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1053\/euhj.1998.1242","article-title":"Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide","volume":"20","author":"Klepzig","year":"1999","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.numecd.2020.05.032_bib20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/clc.4960230713","article-title":"Effects of glibenclamide, a K(ATP) channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectoris","volume":"23","author":"Ovunc","year":"2000","journal-title":"Clin Cardiol"},{"issue":"9","key":"10.1016\/j.numecd.2020.05.032_bib21","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.2337\/db15-1737","article-title":"Cerebrovascular safety of sulfonylureas: the role of KATP channels in neuroprotection and the risk of stroke in patients with type 2 diabetes","volume":"65","author":"Liu","year":"2016","journal-title":"Diabetes"},{"issue":"5 Pt 1","key":"10.1016\/j.numecd.2020.05.032_bib22","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1016\/S0002-8703(99)70034-7","article-title":"Therapy of type 2 diabetes, cardiovascular death, and the UGDP","volume":"138","author":"Feinglos","year":"1999","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.numecd.2020.05.032_bib23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.1980.03300310038020","article-title":"The achilles heel of the university group diabetes Program","volume":"243","author":"Kilo","year":"1980","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.numecd.2020.05.032_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00045391-200603000-00009","article-title":"Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs","volume":"13","author":"Johnsen","year":"2006","journal-title":"Am J Therapeut"},{"issue":"1","key":"10.1016\/j.numecd.2020.05.032_bib25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/dmrr.411","article-title":"All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides","volume":"20","author":"Mannucci","year":"2004","journal-title":"Diabetes\/metabolism research and reviews"},{"issue":"10","key":"10.1016\/j.numecd.2020.05.032_bib26","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/dom.12116","article-title":"Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials","volume":"15","author":"Monami","year":"2013","journal-title":"Diabetes Obes Metabol"},{"issue":"2","key":"10.1016\/j.numecd.2020.05.032_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1503\/cmaj.050748","article-title":"Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study","volume":"174","author":"Simpson","year":"2006","journal-title":"CMAJ (Can Med Assoc J) : Canadian Medical Association journal = journal de l'Association medicale canadienne"},{"issue":"5 Suppl 1","key":"10.1016\/j.numecd.2020.05.032_bib28","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.metabol.2006.02.004","article-title":"Sulfonylureas and the risk of myocardial infarction","volume":"55","author":"Thisted","year":"2006","journal-title":"Metab, Clin Exp"},{"issue":"5","key":"10.1016\/j.numecd.2020.05.032_bib29","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2337\/dc16-1943","article-title":"Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies","volume":"40","author":"Azoulay","year":"2017","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.numecd.2020.05.032_bib30","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/dom.12967","article-title":"Cardiovascular safety of insulin: between real-world data and reality","volume":"19","author":"Mannucci","year":"2017","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2020.05.032_bib31","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","author":"Rosenstock","year":"2019","journal-title":"Jama"},{"key":"10.1016\/j.numecd.2020.05.032_bib32","doi-asserted-by":"crossref","first-page":"107836","DOI":"10.1016\/j.diabres.2019.107836","article-title":"The right place for Sulphonylureas today","volume":"157","author":"Webb","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"10.1016\/j.numecd.2020.05.032_bib33","article-title":"The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials","volume":"13","author":"Varvaki Rados","year":"2016","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.numecd.2020.05.032_bib34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2213-8587(14)70213-X","article-title":"Mortality risk among sulfonylureas: a systematic review and network meta-analysis","volume":"3","author":"Simpson","year":"2015","journal-title":"The lancet Diabetes & endocrinology"},{"issue":"1","key":"10.1016\/j.numecd.2020.05.032_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0029-1211414","article-title":"Sulfonylurea receptors and mechanism of sulfonylurea action","volume":"104","author":"Panten","year":"1996","journal-title":"Exp Clin Endocrinol Diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association"},{"issue":"11","key":"10.1016\/j.numecd.2020.05.032_bib36","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.2337\/dc17-0595","article-title":"Pharmacologic differences of sulfonylureas and the risk of adverse cardiovascular and hypoglycemic events","volume":"40","author":"Douros","year":"2017","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.numecd.2020.05.032_bib37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2337\/dc17-0294","article-title":"Comparative safety of sulfonylureas and the risk of sudden cardiac arrest and ventricular arrhythmia","volume":"41","author":"Leonard","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.numecd.2020.05.032_bib38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/dmrr.642","article-title":"Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin","volume":"22","author":"Monami","year":"2006","journal-title":"Diabetes\/metabolism research and reviews"},{"issue":"1","key":"10.1016\/j.numecd.2020.05.032_bib39","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4103\/ijem.IJEM_556_17","article-title":"Consensus Recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus - international task force","volume":"22","author":"Kalra","year":"2018","journal-title":"Indian journal of endocrinology and metabolism"},{"issue":"4","key":"10.1016\/j.numecd.2020.05.032_bib40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.numecd.2020.05.032_bib41","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.numecd.2020.05.032_bib42","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1464-5491.2004.01426.x","article-title":"A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial","volume":"22","author":"Charbonnel","year":"2005","journal-title":"Diabet Med : a journal of the British Diabetic Association"},{"issue":"5","key":"10.1016\/j.numecd.2020.05.032_bib43","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0149-2918(04)90074-4","article-title":"Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial","volume":"26","author":"Derosa","year":"2004","journal-title":"Clin Therapeut"},{"issue":"9833","key":"10.1016\/j.numecd.2020.05.032_bib44","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/S0140-6736(12)60479-6","article-title":"Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial","volume":"379","author":"Gallwitz","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.numecd.2020.05.032_bib45","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1253\/circj.CJ-11-1011","article-title":"Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients","volume":"76","author":"Kataoka","year":"2012","journal-title":"Circ J : official journal of the Japanese Circulation Society"},{"issue":"8","key":"10.1016\/j.numecd.2020.05.032_bib46","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/dom.12933","article-title":"Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged >\/= 60 years (START-J trial)","volume":"19","author":"Terauchi","year":"2017","journal-title":"Diabetes Obes Metabol"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475320302258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475320302258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:14:00Z","timestamp":1760544840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475320302258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0939475320302258"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2020.05.032","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of insulin secretagogues on major cardiovascular events and all-cause mortality: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2020.05.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}